The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.

@article{Kanelleas2011TheRO,
  title={The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.},
  author={Antonios I Kanelleas and Charis Liapi and Alexandros Katoulis and Panayiotis G Stavropoulos and Georgia Avgerinou and Sophia Georgala and Th Economopoulos and Nicolaos G. Stavrianeas and Andreas D Katsambas},
  journal={Clinical and experimental dermatology},
  year={2011},
  volume={36 8},
  pages={845-50}
}
BACKGROUND Psoriasis is a chronic, systemic, inflammatory disease. Inflammatory markers are used in clinical practice to detect acute inflammation, and as markers of treatment response. Etanercept blocks tumour necrosis factor (TNF)-α, which plays a central role in the psoriatic inflammation process. AIM To reveal any possible association between disease severity [measured by Psoriasis Area and Severity Index (PASI)] and the inflammatory burden (measured by a group of inflammatory markers… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…